



**Contact:**

Douglas Doerfler  
Chief Executive Officer  
MaxCyte, Inc.  
(301) 517-5556

**For Immediate Release**

**TheraMed becomes MaxCyte™**

**Rockville, MD, October 1, 2001** -- MaxCyte today announced the launch of its new name and logo. MaxCyte, a privately held biotechnology company, is focused on the development of therapeutic products based on its “gemocytic” cell loading technology platform. MaxCyte was previously known as TheraMed, Inc.

In a statement to the press, Mr. Douglas Doerfler, MaxCyte’s President and CEO, explained the change. “The name MaxCyte more accurately reflects our business and strategic direction. Our platform technology leverages the natural functions of a cell by loading it with a bioactive substance to maximize its effectiveness in disease states.”

“The name also creates an image of an advanced drug delivery technology directed to the site of disease, and further embodies our strategy to commercialize the technology.” Mr. Doerfler continued, “Currently, MaxCyte has a product, ErythroMax™, in Phase I clinical trials. ErythroMax™ enhances oxygen delivery, and clearly demonstrates our capability to bring exciting new therapeutics from the bench to the bedside.

Dr. John Holaday, MaxCyte co-founder and Chairman, stated: “I am proud of the efforts made by our MaxCyte team to bring our cell permeation technology forward as a potential therapeutic and as a drug delivery platform for genes and drugs. Changing the name from TheraMed to MaxCyte marks the transition for our company to a clinical-stage biopharmaceutical company.”

MaxCyte is a clinical stage biotechnology company developing targeted therapeutic products to treat severe and chronic diseases, including cancer, serious infections, cardiovascular disease and genetic disorders, based on its proprietary technology that uses blood cells for drug and non-viral gene delivery. MaxCyte is majority owned by EntreMed, Inc. For further information, please visit the MaxCyte web site at <http://www.MaxCyte.com>.

EntreMed, Inc., The Angiogenesis Company(TM), (NASDAQ: ENMD) is a clinical-stage biopharmaceutical company emphasizing antiangiogenesis therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer, blindness and atherosclerosis. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories. For further information, please visit the EntreMed web site at <http://www.entremed.com>.

*This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.*

#####

